Cancer

2022 cancer statistics with a focus on lung cancer

This Plain Language Summary of Publication from Future Oncology describes the data from an article entitled ‘ Cancer statistics, 2022’ which provided detailed information about lung cancer and predicted the number of new cancer diagnoses and deaths there would be in the United States in 2022. Read the full article here The original article on […]
A Plain Language Summary with patient perspective’s of the revised STARS study: Long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung cancer (NSCLC)

This Plain Language Summary of Publication from Future Oncology describes the results from a study which compared how effective radiotherapy is compared to surgery when used to treat non-small-cell lung cancer, also known as NSCLC. Read the full article here. The original article on which this Plain Language Summary of Publication is based is titled […]
A Plain Language Summary and a patient perspective of the 2020 lung cancer screening recommendations given by the US Preventive Services Task Force

This Plain Language Summary of Publication from Future Oncology describes the research carried out by the United States Preventive Services Task Force where they reviewed how successful a type of scan called low dose computed tomography was in finding lung cancer in people who hadn’t shown any physical signs of it. Read the full article […]
A Plain Language Summary and a patient perspective of the American Society for Clinical Oncology guideline: management of stage 3 non-small-cell lung cancer

This Plain Language Summary of Publication from Future Oncology describes the guideline written by the American Society for Clinical Oncology on the management of stage 3 non-small-cell lung cancer, also known as NSCLC. Read the full article here. The original article on which this Plain Language Summary of Publication is based is titled ‘Management of […]
A Plain Language Summary and a patient perspective of the recommendations made by the European Society for Medical Oncology on treating EGFR-positive non-small-cell lung cancer

This Plain Language Summary of Publication from Future Oncology describes the new set of recommendations made by the European Society for Medical Oncology (ESMO) which cover the management of people with a type of lung cancer called epidermal growth factor receptor-positive non-small-cell lung cancer (EGFR-positive NSCLC). Read the full article here. The original article on […]
Plain Language Summary: managing metastatic prostate cancer by integrating radium-223 therapy

This Plain Language Summary Publication from Future Oncology provides an overview of the current treatments available for metastatic castration-resistant prostate cancer (mCRPC) and also looks at what might be the best timing to use radium-223 therapy. Read the full article here.
Plain Language Summary: the CheckMate 274 study, treatment of muscle-invasive urothelial cancer with nivolumab

This Plain Language Summary Publication from Future Oncology describes the results from a study called CheckMate 274 which looked at a new medication called nivolumab and how well it worked to reduce the chance of muscle-invasive urothelial cancer returning after surgery. Read the full article here. The original article on which this Plain Language Summary […]
Plain Language Summary: the CheckMate 816 study, nivolumab plus chemotherapy given before surgery for NSCLC

This Plain Language Summary Publication from Future Oncology describes the results from an ongoing study which looks at whether a medication called nivolumab plus chemotherapy works better than chemotherapy alone when given before surgery in people with non–small-cell lung cancer (NSCLC) that can be removed surgically. Read the full article here. The original article on […]
Plain Language Summary: a real-world database analysis on prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor

This Plain Language Summary of Publication from Future Oncology describes the results from a study looking at whether combining a second treatment (palbociclib) with an aromatase inhibitor helped people with HR+ breast cancer live longer. Read the full article here. The original article on which this plain language summary is based is titled ‘Real-world study […]
Plain Language Summary : iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström’s macroglobulinemia

This Plain Language Summary of Publication from Future Oncology describes the results of a 5-year study comparing combinations of drugs for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cell cancer. Read the full article here The original article on which this Plain Language Summary of Publication is based is titled ‘Ibrutinib Plus Rituximab […]
Plain Language Summary: Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations

This Plain Language Summary Publication from Future Oncology describes the results from a study which describes how effective a medication called Afatinib is in people who have non-small-cell-lung cancer (NSCLC) caused by unusual mutations. Read the full article here. The original article on which this plain language summary is based is titled ‘Afatinib for the […]
Plain Language Summary: the development and validation of risk calculators for people with “thin” melanomas on their skin to predict the likelihood that their cancer will return

This Plain Language Summary from Future Oncology describes the development of risk calculators, for people with “thin” melanoma, to predict the likelihood of their cancer returning. Read the full article here. The original article on which this Plain Language Summary is based is titled ‘Development and Validation of Nomograms to Predict Local, Regional, and Distant […]
Plain Language Summary: the CheckMate 649 study compares nivolumab in combination with chemotherapy with chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus

This Plain Language Summary of Publication from Future Oncology describes the results from a study called CheckMate 649, the study looked into whether combining Nivolumab , an immunotherapy, with chemotherapy would help people with advanced stomach or oesophageal cancer live longer without their cancer getting worse. Read the full article here. The original article on […]
Plain language summary of a fingerprinting technique to monitor blood cancer

This plain language summary describes a study in which researchers investigated a new tool called Raman spectroscopy in the detection and monitoring of blood cancer.
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary

This plain language summary from Future Oncology describes long-term results from the RESONATE-2 study in which participants were treated with ibrutinib or with chlorambucil, and then followed for up to 8 years.
Testing methods to diagnose TRK fusion cancer – a plain language summary and patient perspective

This plain language summary describes a study that looked at the different tests used to detect a rare type of cancer called TRK (tropomyosin receptor kinase) fusion cancer in people taking part in three clinical trials testing the medication larotrectinib.
A plain language summary of daratumumab plus lenalidomide / bortezomib / dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study

This plain language summary published in Future Oncology describes results for the Black participants of the GRIFFIN clinical study, which looked at the treatment combination of daratumumab plus a standard therapy for multiple myeloma (called RVd therapy).
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?

Read the plain language summary of an analysis of the PROSPER study looking at whether patient traits affect survival in people with advanced prostate cancer who are treated with enzalutamide compared to placebo.
Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?

This plain language summary provides an overview of a real-world study involving men with advanced prostate cancer using medical information from the Veterans Health Administration.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study

Understand the results of the PHERGain study looking at whether a type of imaging can identify people with HER2-positive early breast cancer who are more likely to benefit from treatment with trastuzumab and pertuzumab without the need for chemotherapy.
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

Read about the ongoing TALAPRO-2 study looking at the combination of talazoparib and enzalutamide as a first treatment in adult men with metastatic castration-resistant prostate cancer.
Plain language summary of outcomes in people treated for lung squamous cell cancer with afatinib after receiving pembrolizumab with chemotherapy

This new plain language summary from Future Oncology can help people understand if the treatment afatinib could be an option for people who have already been treated for metastatic squamous cell carcinoma of the lung with pembrolizumab plus chemotherapy.
Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs

This plain language summary reports the findings of a recent review looking at the background and studies of different treatments for NRG1 fusion-positive cancers.
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

Summary and patient perspectives of the ARASENS trial looking at treatment with darolutamide compared to placebo in combination with docetaxel and androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer.
Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer

This is plain language summary provides an overview of the HERO study looking at how well relugolix works, compared with leuprolide, in men with advanced prostate cancer.
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer

This new plain language summary explains the results of the JAVELIN Bladder 100 study, which looked at avelumab maintenance treatment in people with advanced urothelial cancer.
A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma

A new plain language summary discussing the results of a clinical study that looked at the use of two immunotherapy drugs, pembrolizumab and ipilimumab, for the treatment of advanced melanoma.
Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer

A new plain language summary of a case series, which looked at how well a drug called afatinib worked in people who have a rare type of cancer called neuregulin-1 (also called NRG1) gene fusion-positive cancer.
Plain language summary of INSIGHT 2: a study to learn about the effects and safety of tepotinib plus osimertinib in patents with a type of non-small cell lung cancer

Read about the ongoing INSIGHT 2 study looking at the effects and safety of tepotinib combined with osimertinib, in patients with lung cancer that has stopped responding to osimertinib because of resistance.
Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary

Read this plain language summary to understand how people from different ethnic groups respond differently to treatments for non-small cell lung cancer.
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer

The new plain language summary helps people understand the results of the ADAURA study of osimertinib in a type of non-small cell lung cancer.
Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study

Read the plain language summary discussing the result of the INVICTUS study looking at ripretinib as a potential treatment for advanced gastrointestinal stromal tumor.
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer

This plain language summary helps patients with untreated non-small cell lung cancer learn about the results of the CROWN study.
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

The latest plain language summary describes the findings of the ASCENT study looking at sacituzumab govitecan as a treatment for metastatic triple-negative breast cancer.
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

The new plain language summary in Future Oncology helps patients understand the results of the GARNET study of dostarlimab in recurrent or advanced endometrial cancer.
Plain language summary describing the NeoADAURA study in non-small-cell lung cancer

Read the latest supplementary plain language summary published alongside an article in Future Oncology.
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study

Our latest plain language summary helps patients with HER2-positive breast cancer understand the results of the DESTINY-Breast01 study.
Plain language summary of the final results from the GioTag study

Plain language summary of the GioTag study now published in Future Oncology.
Plain language summary of article discussing race and ethnicity of participants in early-phase cancer studies

Discover the latest supplementary plain language summary published in Future Oncology
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial

The latest plain language summary of publication (PLSP) published in Future Oncology provides a summary of the ARAMIS trial.
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)

The first of it’s kind published in a peer-reviewed journal, this article published in Future Oncology provides a lay language summary of the ENLIVEN study.